Renal Transplantation Clinical Trial
Official title:
Influence of Sirolimus and MMF on Vascular Function and Markers of Cellular Function in Renal Transplant Recipients - Positive Effects of Calcineurin-free Immunosuppression
Chronic transplant nephropathy and cardiovascular death are the main reasons for loss of
transplanted organs after kidney transplantation.
Vascular changes, induced by hypertension and/or immunological processes, determine long
time transplant survival.
It will be tested whether the withdrawal of calcineurininhibitors will improve the vessel
wall function in renal transplant patients. It is supposed that this immunosuppressive
regimen reduces the activation of endothelial cells with important impact on
arteriosclerosis and therefore on patient and transplant survival.
Cardiovascular complications and chronic rejection are chief causes of transplant loss[1,2].
After renal transplantation patients are still characterized by their pre-existing
arteriosclerotic changes [3]. Endothelial dysfunction and disturbed distensibility of great
arteries are independent predictors of cardiovascular morbidity [4,5]. Additionally the
activation of sympathetic nervous system leads to dysfunction of vessel wall[6,7]. There are
important therapeutic options in improvement of endothelial function [8].
In addition monocytes of the recipient will contribute to vessel wall changes. [9-11]. Aim
of therapy - especially of immunosuppressive therapy- have to prevent these fatal vessel
wall changes.
Therefore in this study the following topics will be addressed.
1. Discontinuing of calcineurininhibitors will lead to improvement of vessel wall function
2. Sirolimus and Mycophenolat Mofetil affect vessel wall properties in a different way.
3. There are risk factors, e.g. activity of sympathetic nervous system, which may determine
the efficacy of discontinuing the calcineurininhibitor concerning the vessel wall function.
4. Calcineurininhibitorfree immunosuppression reduces the activity of endothelial cells.
5. Survival of monocytes and release of procoagulatory activity will be changed by the
immunosuppressive regimen.
1. Rostand SG, Brunzell JD, Cannon RO, Victor RG. Cardiovascular complications in renal
failure. J Am Soc Nephrol. 1991; 2: 1053-1062
2. London GM, Druecke TB. Atherosclerosis and arteriosclerosis in chronic renal failure.
Kidney Int 1997; 51(6):1678-1695.
3. Hausberg, M., K. Kisters, M. Kosch, K. H. Rahn, and M. Barenbrock. Flow-mediated
vasodilation and distensibility of the brachial artery in renal allograft recipients.
Kidney Int. 55: 1104-1110, 1999.
4. Barenbrock M, Kosch M, Jöster E, Kisters K, Rahn KH, Hausberg M: Reduced arterial
distensibility is a predictor of cardiovascular disease in patients after renal
transplantation. Journal of Hypertension 2002, 20:79-84.
5. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FHM, Marchais SY. Forearm
reactive hyperemia and mortality in end-stage-disease. Kidney Int 2004, 65:700-704.
6. Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Fouad-Tarazi F, Victor RG.
Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992;
327:1912-1918.
7. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH.
Sympathetic nerve activity in end-stage renal disease. Circulation. 2002, 106:1974-9.
8. Kosch M, Barenbrock M, Kisters K, Rahn KH, Hausberg M. Relationship between muscle
sympathetic nerve activity and large artery mechanical vessel wall properties in renal
transplant patients. J Hypertens. 2002, 20:501-8.
9. Österud, A., Björklid E. Role of monocytes in atherogenesis. Physiological reviews,
2003, 83: 1069-1112.
10. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan
14;340(2):115-26.
11. Lessner SM, Prado HL, Waller EK, Galis ZS. Atherosclerotic lesions grow through
recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol.
2002 Jun;160(6):2145-55.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Active, not recruiting |
NCT02444429 -
3-month Screening Biopsy to Optimize the Immunosuppression in Renal Transplantation
|
Phase 3 | |
Completed |
NCT02238418 -
Efficacy of Usual Vitamin D Supplementation and Its Impact on Children and Adolescents Calciuria.
|
Phase 4 | |
Completed |
NCT01729494 -
Belatacept Early Steroid Withdrawal Trial
|
Phase 4 | |
Terminated |
NCT01436305 -
Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
|
Phase 2 | |
Completed |
NCT02843295 -
Catalytic Antibodies to Predict Uninvasively Late Transplant Failure
|
N/A | |
Terminated |
NCT01276834 -
Comparison of Immunosuppression on Progression of Arteriosclerosis in Renal Transplantation
|
Phase 4 | |
Completed |
NCT00842699 -
Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
|
N/A | |
Completed |
NCT00525681 -
Interaction Between Rimonabant and Cyclosporine and Tacrolimus
|
Phase 4 | |
Completed |
NCT00776750 -
Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
|
Phase 4 | |
Completed |
NCT00189735 -
A Study to Evaluate FK778 in Kidney Transplant Patients
|
Phase 2 | |
Recruiting |
NCT04052867 -
Intravenous Lignocaine Infusion in Laparoscopic Donor Nephrectomy
|
N/A | |
Recruiting |
NCT03114826 -
Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients
|
N/A | |
Completed |
NCT02587052 -
A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac
|
||
Completed |
NCT02020642 -
Effect of Renal Transplantation on Obstructive Sleep Apnea in End Stage Renal Disease Patients (SASinTx)
|
N/A | |
Completed |
NCT01435291 -
AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation
|
Phase 4 | |
Recruiting |
NCT01001065 -
Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis
|
N/A | |
Completed |
NCT00978965 -
Identification of Patients With High Probability of Poorly Responding to Therapy With Mycophenolic Acid Prodrugs
|
||
Recruiting |
NCT00903188 -
Calcineurin Inhibitor (CNI) Versus Steroid Cessation in Renal Transplantation
|
Phase 4 | |
Completed |
NCT00400400 -
Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance
|
Phase 4 |